Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
30
NLSP Quote, Financials, Valuation and Earnings
Last price:
$1.83
Seasonality move
:
0.34%
Day range:
$1.83 - $1.96
52-week range:
$1.73 - $24.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
39.5K
Avg. volume:
371.8K
1-year change:
-89.14%
Market cap:
$7.2M
Revenue:
--
EPS (TTM):
-$6.74
Analysts' Opinion
-
Consensus RatingNLS Pharmaceutics has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, NLS Pharmaceutics has an estimated upside of 12574.27% from its current price of $1.89.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $1.89.
Fair Value
-
According to the consensus of 0 analysts, NLS Pharmaceutics has 12574.27% upside to fair value with a price target of -- per share.
NLSP vs. S&P 500
-
Over the past 5 trading days, NLS Pharmaceutics has underperformed the S&P 500 by -0.57% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
NLS Pharmaceutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
NLS Pharmaceutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter NLS Pharmaceutics reported revenues of --.
Earnings Growth
-
NLS Pharmaceutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter NLS Pharmaceutics reported earnings per share of --.
Enterprise value:
8.4M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.14x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-25 | 2023-12-25 | 2023-12-25 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $221.3K | $8.2M | $2M | $2.2M | $1.2M | |
| Total Assets | $640K | $8.3M | $2.1M | $2.3M | $1.2M | |
| Current Liabilities | $4.7M | $1.2M | $3.4M | $3.9M | $7.7M | |
| Total Liabilities | $8M | $4M | $6.1M | $6.6M | $10.5M | |
| Total Equity | -$7.3M | $4.2M | -$4M | -$4.3M | -$9.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-25 | 2023-12-25 | 2023-12-25 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
NLSP
Sector
Market Cap
$7.2M
$46.1M
Price % of 52-Week High
7.78%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-89.15%
-30.52%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.97
200-day SMA
Sell
Level
$5.83
Bollinger Bands (100)
Sell
Level
3 - 6.36
Chaikin Money Flow
Sell
Level
-162.1M
20-day SMA
Sell
Level
$2.35
Relative Strength Index (RSI14)
Sell
Level
33.66
ADX Line
Sell
Level
17.59
Williams %R
Buy
Level
-84.566
50-day SMA
Sell
Level
$3.35
MACD (12, 26)
Sell
Level
-0.43
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
453.6M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
Stock Forecast FAQ
In the current month, NLSP has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NLSP average analyst price target in the past 3 months is --.
-
Where Will NLS Pharmaceutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that NLS Pharmaceutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About NLS Pharmaceutics?
Analysts are divided on their view about NLS Pharmaceutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that NLS Pharmaceutics is a Sell and believe this share price will drop from its current level to --.
-
What Is NLS Pharmaceutics's Price Target?
The price target for NLS Pharmaceutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NLSP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for NLS Pharmaceutics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NLSP?
You can purchase shares of NLS Pharmaceutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase NLS Pharmaceutics shares.
-
What Is The NLS Pharmaceutics Share Price Today?
NLS Pharmaceutics was last trading at $1.83 per share. This represents the most recent stock quote for NLS Pharmaceutics. Yesterday, NLS Pharmaceutics closed at $1.89 per share.
-
How To Buy NLS Pharmaceutics Stock Online?
In order to purchase NLS Pharmaceutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
